News | May 25, 2022
Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
The cash consideration for the acquisition is US$ 18 million.
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The company has strong product launches both in India and overseas
Arrow is the marketing partner in US
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
TFOS is indicated for the treatment of pulmonary arterial hypertension
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Subscribe To Our Newsletter & Stay Updated
